Galectin Therapeutics CMO Jamil Khurram Exercises Options and Sells Shares

On July 14, 2026, Jamil Khurram, Chief Medical Officer of Galectin Therapeutics Inc., exercised stock options for 16,250 shares at $3.04 per share and immediately sold all 16,250 shares at a weighted average price of $5.1252 per share. The transactions were executed pursuant to a Rule 10b5-1 plan adopted on February 2, 2026, as disclosed in the company's Form 10-Q filed on May 15, 2026. The stock options were part of a vesting schedule that began on June 30, 2026. Following these transactions, Khurram holds 48,750 remaining stock options but no direct shares of common stock. The sale was conducted in multiple transactions at prices ranging from $5.00 to $5.32 per share.